Brand Reference: Ozempic, Wegovy, Rybelsus
| Metric | Verified Benchmark | Source |
|---|---|---|
| Semaglutide RxNorm Concept ID | 1991302 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $234.1800 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $1048.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $199.00 / mo (Direct TeleMed) | Direct Telehealth Formulary |
| Community Mean Out-of-Pocket Paid | $245.00 / mo | 42 Zero-PHI Verified Patient Logs |
Acylated human glucagon-like peptide-1 analogue with 94% sequence homology that binds pancreatic and hypothalamic GLP-1 receptors, amplifying glucose-dependent insulin secretion, suppressing postprandial glucagon, delaying gastric emptying, and dampening arcuate nucleus appetite signaling.
Classified under GLP-1 Receptor Agonist (Rx), Semaglutide exhibits a $803.00/month gap between standard U.S. retail cash counters ($1048.00) and verified direct-to-patient routing ($245.00) anchored to $234.1800 CMS unit cost.
Pharmacokinetic profiling of Semaglutide demonstrates an elimination half-life of ~168 hours (7 days) with 89% subcutaneous / ~1% oral SNAC systemic bioavailability; clearance proceeds via proteolytic cleavage & beta-oxidation of fatty diacid side chain, reaching clinical onset within 24–72 hours glycemic; 4–8 weeks steady state.
Titration schedules for Semaglutide (0.25 mg SC weekly → 0.5 mg SC weekly → 1.0 mg SC weekly → 1.7 mg SC weekly → 2.4 mg SC weekly) require excluding medullary thyroid carcinoma history; multiple endocrine neoplasia syndrome type 2; prior severe pancreatitis or hypersensitivity; real-world patient logs highlight nausea (34% of reports), early satiety (28% of reports), constipation (19% of reports) alongside a 89.40% Worth-It consensus.
Across 42 verified cash-pay logs, Semaglutide achieves a 89.40% Worth-It rating with out-of-pocket spend averaging $245.00/mo versus $1048.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 0.25 mg SC weekly for Semaglutide; monthly out-of-pocket dropped to $215.60 compared with $1048.00 retail.
Completed 10 weeks on Semaglutide (0.5 mg SC weekly). Zero notable side effects on steady dosing.
Consistent biomarker response on 1.0 mg SC weekly Semaglutide sourced via TeleMed ($284.20/mo cash pay without insurance prior authorization).